🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10745471

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738124

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738130

Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738126

Anti-GITR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10737113

Human antibodies to PD-1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736976

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736961

Method of averting opioid addiction

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10730948

Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10730944

Anti-CD8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10711032

Steroids and protein-conjugates thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10689436

Human antibodies to influenza hemagglutinin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683354

Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676530

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10662244

Methods for tumor treatment using CD3XCD20 bispecific antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10640566

Nucleic acid molecules encoding antibodies to the human glucagon receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10640558

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10633434

Anti-C5 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10632194

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10626173

Method for treating pathological angiogenesis by administering an antibody that inhibits A

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10618968

Antigen-binding proteins that activate the leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10588940

Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulat

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10584173

Nucleic acids encoding high affinity antibodies to human IL-6 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10582702

Non-human animals having an engineered ANGPTL8 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10570151

Biologically active molecules, conjugates thereof, and therapeutic uses

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted